SLC5A2 and diabetes mellitus: Drugs inhibiting SGLT2 were initially registered in the treatment of diabetes mellitus type 2 (canagliflozin, dapagliflozin, empagliflozin ertugliflozin), and afterwards, dapagliflozin was also used in treatment of diabetes mellitus type 1.